Unloxcyt™ (cosibelimab-ipdl) – New drug approval
December 13, 2024 - Checkpoint Therapeutics announced the FDA approval of Unloxcyt (cosibelimab-ipdl), for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.